Micronized compositions for wound healing prepared from intact human amnion-chorion tissue having an intact intermediate spongy layer positioned there between
A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.
1 . A sterile micronized composition prepared from intact human placental tissue, the sterile micronized composition comprising:
(a) micronized human amnion;
(b) micronized human chorion; and
(c) micronized human intermediate spongy layer;
wherein the composition is prepared from intact placental tissue in cross-section comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between and connecting the human amnion layer to the human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another;
wherein the composition is prepared without the use of exogenous enzymes; and
wherein the composition comprises HA ranging from 1.0×10 7 to 1.0×10 8 pg/cm 2 ; and at least two of the following:
(a) IL-1ra ranging from 1.0×10 2 to 5.0×10 4 pg/cm 2 ;
(b) HGF ranging from 5.0×10 2 to 1.0×10 4 pg/cm 2 ;
(c) VEGFR1 ranging from 5.0×10 2 to 5.0×10 3 pg/cm 2 ;
(d) GAGs; and
(e) Collagen.
2 . The sterile micronized composition of claim 1 , wherein the micronized human amnion comprises 10% to 20% of the total weight of the sterile micronized composition.
3 . The sterile micronized composition of claim 2 , wherein the micronized human chorion comprises 65% to 75% of the total weight of the sterile micronized composition.
4 . The sterile micronized composition of claim 3 , wherein the micronized human intermediate spongy layer comprises 10% to 20% of the total weight of the sterile micronized composition.
5 . The sterilized micronized composition of claim 1 , wherein the sterile micronized composition is sterilized by e-beam sterilization.
6 . The sterile micronized composition of claim 1 , wherein the composition comprises at least four of the following:
(a) IL-1ra ranging from 1.0×10 2 to 5.0×10 4 pg/cm 2 ;
(b) HGF ranging from 5.0×10 2 to 1.0×10 4 pg/cm 2 ;
(c) VEGFR1 ranging from 5.0×10 2 to 5.0×10 3 pg/cm 2 ;
(d) GAGs; and
(e) Collagen.
7 . The sterile micronized composition of claim 6 , wherein the composition comprises each of the following:
(a) IL-1ra ranging from 1.0×10 2 to 5.0×10 4 pg/cm 2 ;
(b) HGF ranging from 5.0×10 2 to 1.0×10 4 pg/cm 2 ;
(c) VEGFR1 ranging from 5.0×10 2 to 5.0×10 3 pg/cm 2 ;
(d) GAGs; and
(e) Collagen.
8 . The sterile micronized composition of claim 1 , wherein the micronized human amnion comprises diameters ranging from 1 μm to 500 μm.
9 . The sterile micronized composition of claim 1 , wherein the micronized human chorion comprises diameters ranging from 1 μm to 500 μm.
10 . The sterile micronized composition of claim 1 , wherein the micronized human intermediate spongy layer comprises diameters ranging from 1 μm to 500 μm.
11 . The sterile micronized composition of claim 1 , wherein the micronized composition is not cryofractured.
12 . The sterile micronized composition of claim 1 , wherein the sterile micronized composition is standardized to the weight of sterile, dehydrated, micronized placental tissue.
13 . The sterile micronized composition of claim 12 , wherein the sterile micronized composition is standardized by the following:
factor
assayed
(
pg
/
ml
)
*
(
ml
of
eluate
)
mg
particulate
=
pg
of
growth
facter
per
mg
.
14 . The sterile micronized composition of claim 1 , wherein the micronized composition is configured for wound packing, treatment of wounds having irregular surfaces and/or peripheral boundaries, weeping wounds, dental and/or oral wounds and/or incisions, or any combination thereof.
15 . A medicament comprising the composition of claim 1 .
16 . A therapeutic aerosol comprising the composition of claim 1 configured for intranasal and/or pulmonary administration to a subject in need thereof.
17 . The therapeutic aerosol of claim 16 configured to treat pulmonary disorders, trachea disorders, and a combination thereof.
18 . A therapeutic bandage comprising the composition of claim 1 configured for topical wound treatment to a subject in need thereof.
19 . The therapeutic bandage of claim 18 , wherein the therapeutic bandage comprises a cellulose matrix, a polymeric matrix, or a combination thereof embedded with the sterile micronized composition.
20 . The therapeutic bandage of claim 19 , wherein the cellulose matrix comprises a carboxyalkyl cellulose matrix or a hydroxyalkyl cellulose matrix.
21 . The therapeutic bandage of claim 19 , wherein the therapeutic bandage is configured to time release the sterile micronized composition to the wound over a predetermined time-period.